Short-term feasibility studies of the 8 lead compounds in reducing Aβ neuropathology in Tg2576 mouse model of AD.

<p>Tg2576 mice were treated with 2 mg/kg/day of the candidate compound delivered through their drinking water for 4 weeks, Body weight, brain neuropathology including oligomeric Aβ as well as total brain Aβ were compared to vehicle-treated control Tg2576 mice (n = 5 per group, *p<0.05).